APYX - Earnings call 3 2023 | Apyx Medical Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and welcome, ladies and gentlemen, to the Third Quarter of Fiscal Year 2023 Earnings Conference Call for Apyx Medical Corporation. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that can cause actual results to differ materially from those indicated, including without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise. include in certain accounting accordance GAAP. also are measures principles will calculated not with call references financial to that or This generally accepted generally measures. non-GAAP We these financial to refer as the Reconciliations non-GAAP website. portion presented accordance release release GAAP of with of on earnings measures available the earnings financial to our in in those are -- calculated most measures the and comparable press Relations Investor call over would to turn now I like the to Mr. Executive Goodwin, Apyx Medical's Charlie Chief Officer. and President go Please ahead.

Charles Goodwin

to our I'm everyone, quarter of call Thanks, our call. welcome, operator, Officer, third XXXX earnings joined by and today's on Tara Chief Financial Semb.

Let operational I'll outline discuss of begin guidance, progress detail made of some our remarks during which our provide an quarter revenue review share achieved what today. with revenue our with in along discussing by cover of then quarter we financial our team in a will third open has our to me to today. that, Tara I'll a in million. third updated recent months. by results, our the you the we and results on brief financial the $XX followed let's questions. intend call additional results. growth quarter, the begin with we year-over-year third With XXXX total for In earnings XX% closing revenue we before release update

sales million, to advanced energy our year-over-year XX% $X.X fueled products, of increased to of while sales Our by total our primarily million. growth revenue increased year-over-year OEM $X.X was X% which products

see were contributions geographies. total Advanced U.S. we growth closely, our from Energy and more of both the year-over-year notable delivered pleased of the $X.X that in the million revenue performance to Advanced at year-over-year, we international Looking Energy segment

In XX% by year-over-year, energy performance XX%. of Our pieces. that along generator in fueled sales year-over-year U.S. which increased exceeded was with nearly increased global XX% specifically, driven sales products Advanced growth of our growth growth hand double-digit advanced of the our sales our generators, from Energy by sales revenue primarily

quarter of was This by both U.S. Importantly, majority awareness our significant customers. sales a our by of to driven driven in third our of clearances continued raise effort the technology safety console, to the new generator next sales of at by the the our well system, generation which FDA our as this One as year. new Apyx we efficacy and supported Renuvion launched as beginning was

customers, enabling addition to U.S. program, we from a at advantage generation pricing upgrade console by saw took in existing One trading discounted contributions our sales as In to generator sales to well them as to Apyx to important their users our prior they new of the system.

performance in Our factors we minute. more With than generator XX%. our growth saw of XX% sales of offset this the sales that respect Advanced our handpieces performance more to discuss Energy U.S. performance sales in contributed than nearly generator year-over-year handpieces. of international I'll with sales, a flattish to sales increasing

To through this few year-over-year minutes global me versus revenue due recap, by advanced Our walk in international generator saw energy strong regions other third quarter performance sales as primarily was the contributions the of of our all sales expectations. both balanced and primarily market in let quarter in our we advanced generators. driven our our major energy take fueled a was U.S. now well. growth to in third and year-over-year although sales contributions OUS distributors from Latin to With our a from America, to growth and geographic handpiece as XX% growth by you backdrop,

million primarily $XX handpieces, sales in million on the we expected, to provided call. of lower growth than million revenue year-over-year strong expectations basis, than was factors $XX delivered expectations range the in revenue performance generators our we earnings in the a on little our more a total X contributed to delta third range to third believe recent lower-than-expected was energy softer by our driven the the we relative advanced While We quarter advanced of This U.S. quarter. most and our primary energy $X

sales, weaker overall First, respect equipment capital generator cosmetic market guidance for to our assumed. to proved than surgery the with had be

Specifically, as more uncertainty. the we and through we delaying customers third prospective saw capital rates broader citing high economic quarter, equipment purchases, progressed surgeon interest

trends impacted quarter, more The patients potential Second, related the taking seasonal and we on and pronounced vacations. slowness August than procedures. seeking during to in the patients potential hand seasonality years, was our of fewer primarily in recent and sales summer early some with pieces This dynamic we surgeons the third primarily observed we and observed more experienced strong September. vacation

options wait-and-see experiencing to these third, issues, taken marketing to surgeon for surgeons our our end, we flexibility. further a slower-than-expected proactive another potential reason execution we In subsequent take sales financing And in during equipment mitigate quarter capital not with expectations. approach Beginning team. them ultimately to provide proved customers purchasing. made case did meet For future And to steps quarter September, and help sales response volumes, to we our introduced the financial changes and to in our their also marketing it several have impact.

respectively. next-generation our XX% revenue continued generator community. resonating third stockholders system And with while XX% that we this expect and with evidence the XXX(k) in the to completed clearances surgeon team performance our quarter secured were are Stepping loss and recently sales growth our improving attributable see reducing our EBITDA quarter, pleased we the the see from to year-over-year improvements, in are in ultimately importantly, to 'XX with adjusted profitability We net and and softer-than-expected productivity reorganized back, XX% beyond. we disappointed year-over-year, the by

highlights. brief recent of Turning to a discussion operational our

April and in patient for clearances liposuction. regulatory to enabled us to following progress new recent benefits our We made of Renuvion by capitalize both surgeon its continue awareness the aesthetic respect in raise effort our to our technology secure on continued With and years, surgeons, we team at contouring body the to level. XXX(k) which

our latest the We continue on now with use the XXX(k) clearance, handpiece following is APR device indication only with this liposuction. to believe for that market Renuvion the

leveraging prospects on the quarter, procedures. During in these continue third of and prospects, photos, and has continued cosmetic the established safety along efficacy And patient brand team use our of spite new our extensive growth. that earlier, with patients. surgery introduction helped discussed awareness advance video level, actual of headwinds our many the benefit direct-to-consumer real-world on campaign content results developments, developments to new testimonials the and body by achieved and reengage our through will continue we the to for they with after including we products clinical to and potential these we before at patient support In evidence the I been to content, of new educating the believe the focus other have

to about coming addition we technology. engagement our and social Renuvion seeing in expanding receive more In surgeons media, begun have following from asking on incidental patients our to feedback

initiatives, product I One we new and profile important cases appreciate we remain of the our our the handpiece region recommendation generator feedback In feedback Micro facilitate our can new June. the XXX(k) as significantly are ultimately pleased quarter. market obtained market surgeon smaller terms The instrument commenced limited we to July, access benefits launch contraction. clearance and enhance contributor the soft insights generator, the to on surgeon has late shaft training Renuvion our limited target U.S. was release to In provide the have smaller limited commercial to initiate where Micro the as the release of prepare the market tissue securing console, earlier, during our of full date, an release Apyx in with after and participating proved the gathered that year-end. to handpiece brings which in sales Based our mentioned in it next-generation reception to improved handpiece market our customers important we also growth by to

the the that pleased in in In our tax transaction flow we believe we initiatives the driving Revenue of beginning capacity cash agreement quarter sheet today our strong at and we additional of addition capital and our at to that agreement flexibility. and related received sheet with term terms and million Internal new profitability announce and agreement, million the agreement new generating facility significantly senior and $XX our million of approximately of fees we to free to the strategic $X.X financial proceeds $XX.X our of with approved continued which more on approximately prior to we additional the With we the continued profitability us our enhance were driving facility used into us with for transaction. prior requisite pursue of as payment condition entered balance in under sheet sustained overall generation. balance cash balance recent improvements proceeds of to longer-term than enhancing up capital access $XX.X negotiated a flexibility credit million our from closing, to of as towards have growth progress favorable and the the goals the expenses This provides flexibility. refunds other August, while credit And third to our secured our Service year. third million million at agreement quarter, quarter, to strengthening our the financial obligations end perceptive borrowing satisfy for strong profitability X-year $X.X a was at Perceptive under This loans. provided cash they In Advisors well financial the improvements and $XX all

announcement to release Before discuss like to Tara, important earnings call in we turn I an the this I'd press morning. our over made

the Tara's opportunities. announced to company pursue to we lead intention in Specifically, other order

appointed. the to our the appreciate in financial Tara future. Her we results her to and quarter release, near in Financial position Apyx earnings the our been On the behalf Board to process process of January now commitment has successor her made the as release. to appointment Tara? amid formal successor, continued I'd of transition. support announced the a and an I thank Chief team, like we press us turn enabled have As that the expect we of Tara team review important formally look at initiated we the to important the search today's accounting is a financial her and to interim, support today's Officer press growth Medical, strong as Tara's guidance, the and call reporting identified Medical to In Directors an while forward to improve opportunity efforts take analytical updated her continue smooth and XXXX, our joining Since announce develop Apyx her to organization. business. which broader it until contributions in XXXX formal on to in in she third for over to contributor I'll

Tara Semb

time my a member to during as been and team help here. privilege Medical has It serve the Apyx Charlie. develop a Thanks, the of to organization

made my depth With we've financial X like of years positioned financial and look incoming going that believe our Medical transition well and I a and to to forward accounting the CFO. colleagues and the would operational to truly progress thank the the over forward. is their supporting Apyx for support successful I Apyx at last teams,

revenue Given in Gross that are the total otherwise, XXXX or costs, The on a to $X.X driven Loss Charlie benefits of or all due year. or Unless operations percentage driven to sales was X within geographic mix results $XX.X X% international mix financial discussed in line. third higher our $X.X increased sales by Advanced increased profit which comprised million. bonus salaries increases partially margin expenses million. costs. Energy year-over-year to was basis. segments, changes sales. offset primarily XX% gross Energy in to the $X.X by with will our quarter our of as $X.X million increase expense Advanced or higher product was primarily million a and XX%, Operating margin the decreased noted XX% of to to mix largely million. million comprising segment, our begin results, Advanced our profit increase from profit related XX.X% in I for in XX.X% our third quarter and and percentage at the total Energy The references Advanced sales by and and a within Gross $X operating changes between Energy compared gross segment labor million segment expenses GAAP increased last $X.X

by was to $X.X the borrowings quarter, an We to results. compared with The interest stockholders outstanding benefit our outstanding to softer-than-expected XX% year. tax change Income per $X.X $X.XX $X.X we demonstrated $X.X net strong driven the period. leverage million debt $XX,XXX. in are $X.XX Adjusted last was year. to or revenue $X.X or year third net XXXX million income $X.X $X.X million to share expense loss other year. in prior despite $X.X compared EBITDA no to loss decreased the expense pleased related to the XX% or loan to tax million compared million of quarter the or in Total the $XX,XXX expense of per last Net million to attributable compared million income third million last in decreased operating obligations on share of term increase was compared

we stockholders from to loss reminder, detailed in press reconciliation to provided a a EBITDA our As non-GAAP net adjusted earnings attributable loss release.

$X.X net months tax in refunds September the in to in million loss. The generated payment the primarily period. For well improvement receipt the of for was revenue the our cash operating service X internal as compared prior was driven cash of by year used cash improvement for activities to $X.X ended XXXX, as from in cash operating increase XX, an related activities million

XX, had equivalents of of XX, as we million and cash to of cash compared $XX.X As XXXX, XXXX. September million December $XX.X

Turning financial guidance, we to our press release review of a which updated our XXXX today. in earnings

$X.X For $XX This to million compares the expectation to revenue XXXX, an $XX.X -- to representing guidance of $XX XX%, million now which to million, revenue $X assumes XX% total of $XX XX% December or advance OEM we prior revenue Advanced months to expect million to our XX, to Total of growth range $XX.X range our Energy revenue of approximately approximately $XX to XX million. million, compares million of prior XX%. approximately total growth million $XX prior the of compares approximately XX% million, $XX range XX%. in of to of of to and XX%, representing million our our of representing growth which ending increase

$X.X the revenue prior guidance to XXXX, CFO other million full In second XXXX, of loss attributable $XX and terms compared approximately $X.X of our we expenses This of for of updated loss approximately million. related transactions including severance of guidance million expectations our revised approximately now for debt transition. our our our expect loss expectation million reflects $XX.X profitability net half year the related stockholders to to approximately and to of net

guidance purposes. financial XXXX Our following for modeling the formal incorporates for considerations

First, approximately prior compared we to of range XX.X%. guidance the of margins expect gross XX.X% XX% to

on X% lease operating excluding Note, guidance to low compared we now Second, expenses are expect approximately to growth our prior XXXX to X% sale to pack GAAP be year-over-year expected expenses mid-single-digit operating decrease of year-over-year. our year-over-year transaction, the gain up in XXXX.

amortization to other Third, XXXX. $X.X to compared XXXX part fees expect for of our transaction. in million $X.X incurred approximately nonrecurring expense of an versus approximately average expense expense million we expect million guidance net expenses unchanged depreciation of $X.X our total now assumptions. compensation XX.X Note, and $X.X million of approximately $XXX,XXX previously approximately versus debt and assumes noncash prior of $X.X versus stock-based previously, guidance Noncash increase compared interest of by shares. of million million shares And income and our $X.X lastly, our approximately approximately tax net prior The noncontrolling for interest of approximately as $XXX,XXX. million to driven $X million XXXX of approximately weighted diluted of continue previously; we outstanding $XXX,XXX is million, benefit $X.X

I'll on remarks. call results of at $XX cash flow the Charlie proceeds million for assumptions to guidance our turn and $XX With debt fourth updated implies target our that, for December back updated and approximately prior the and quarter. third equivalents to on approximately our transactions the our sheet This our of cash XXXX loss for updated Lastly, net closing million our compared XXXX, net and balance reflects quarter revised in from based cash now million. XX, $XX expectations guidance

Charles Goodwin

Thanks, Tara.

revised As in balance Tara mentioned, third reflects the for performance year. our quarter updated guidance our as our both as of the well the expectations

year-over-year continued following quarter, XXXX expect quarter. our marketing which to equipment revenue contemplates sales fourth improvements the current reorganization advanced the procedure during assumes and our to we related to XX% uncertainty. cosmetic and broader fourth in implies the guidance the And reticent macroeconomic impact of sales of guidance lastly, purchase in team energy sequential financing the surgeons fourth Specifically, of the remain the in the XX% growth assumptions, given our concerns capital strategic surgery will environment volumes quarter

utilization XXXX the One console guidance recent commercial shows. our from We clearances drive to by to updated as like than In Apyx cosmetic our we levels X focus to the continued the strategic conference progress an of all December and next-generation introduction Renuvion Surgeons to new importantly, We is The including trade innovation These revenue immediately energy this that of advantages. expanding addresses technologies them Micro our needs pieces months hand focused programming our applications differentiated achieving position are advanced using evidence continued on we of term. at the standpoint, who our specific for forward. I'd see profitability. technology share $XX other the we And in to of as and of short. respect portfolio the With important support. million of our that to near-term as our and driving team development expectations improve U.S. remain across and Renuvion our XX. dedication years operator, questions. market positioning and recognize despite that with our to technologies recent revenue market. continued represented our surgery of by this now its of committed half for through customers where call its going multibillion-dollar indications, thank we continuing sales recent our on during expand our of initiatives base and progress execution ability our for their shareholders remain surgery of well-established And market, years, utilization. and their after patients partners that, along With loyalty know clinical fact managing best XXX(k) that XX exclusive global technology the Renuvion our have and let's continue by team cosmetic for and we to represents leverage facilitating technology towards raise evidenced drives remaining setbacks, generated made of operational in more and and capabilities initiatives well our global ahead fallen has awareness their the for dedication distributor handpiece closing, us adoption for confident trailing our efforts a more like clinical surgeons than open and of this efforts from direct-to-consumer longer by in mind, expenses with the our our educate lastly, and the the our are range Renuvion ending market our begin customer technology lies bringing true perhaps to using

Operator

will Lake of Markets. [Operator Instructions] from Takkinen Frank question Street our come And first Capital

Frank Takkinen

could hoping was detailed QX. seems the around I Obviously, pretty up a there. good assumptions the just guidance, I but start step heard we with like it still

year? thinking QX? this through you thinking think play year your about you're the on do you half out are from of What's talk learnings seasonality Renuvion normal in be And in QX. maybe could seasonality the handpiece And portion different that how of front how this the the snapback. based So will how the

Charles Goodwin

Frank. Thanks, right. All Yes.

of in as to revenue no XX% we growth year-over-year improvement environment compared implies QX. And in importantly, QX. capital to purchasing guidance updated XX% Our the AE see

the QX volumes QX think procedure environment from compared Same. the would be QX We a sequential we and quarter. reflects time So handpiece capital would QX as more is that in we done and than sales in always also are it made to much see QX fourth in the period. improvement that purchasing changes in our sales team marketing typically And procedures the

Frank Takkinen

that through be if of And effect covenants line. later. about new aware come on little we should any could front bit you then into a maybe any talk the there Can Perceptive there that are talking

Charles Goodwin

Yes.

facility, and months. credit And are So out operational -- secure when made process a us look, facility. of recent took previous position different we've in than new credit lot put pleased the to the in that regulatory, credit financial this and we a we very first has

strengthen and And was so some of to our financial and to pursue the as decision to sheet new as we wanted on the provide balance go it new this us agreement flexibility the -- we made we for keys it covenants strategic more wanted obviously those. far

be were overall. The able terms And new the that. $XX will to to with different capital we growth with capitalized financial we'll we pursue you'll get to more million, to facility it incredibly new creation. things And access what And facility, are up and favorable this well X-K, all so obviously this our to value is itself, has flexibility in and see both so do agreement. the

Operator

line questions next the Sandler. Our come of Matthew O'Brien from with Piper

Matthew O'Brien

luck of endeavors. your I'm Charlie, than from here you little in looking future seen best in we're a tougher to QX historically at got that on about Tara, that thinking we've and a the Maybe steeper environment. QX. up on bump question is and Apyx last following the we've just model

more and you're and challenging in up the I'm October you the wondering macro the bigger what's confidence just that in far environment. So early November seeing so give step in what

Charles Goodwin

that we the our that regulatory compared in in confident sales multiple tailwinds expect have guidance and And reflect updated And is now generator, to the to customers. to very Apyx customers for resonating an after in procedures both organization. though good One where and the better obviously got, both upgrades. specifically that we're asking few can in got that demand sequential as equipment initiatives, a our see beyond only procedure starting think QX. we We've we're are clearances the and QX. still fruition contouring we weaker volumes we even would a of our on the months, obviously, summer our new we've clearance being the States direct-to-consumer improvements patients here do the and we We've And in very doctors body handpiece that really believe saying see our coming made Yes. United to deliver the Look, job still momentum to Renuvion. I reasons. with our ability are this have liposuction and organization purchasing new good environment to capital company changes to We've are but well also for in from with we for

so And in confidence guide. us gives what that's our the QX

Matthew O'Brien

Charlie, did see specifically? you that October in

Charles Goodwin

comment won't strong September, excuse last talking month we had. So we're on very the weeks nice when -- we X necessarily perspective. about sense. But have strong what month we're a from by very demand maintained of December that And from from were level we me, of a

Matthew O'Brien

be follow-up changes I've historically, the adjustments. the take time as then this to the sales specific you're doing force on get a And force watched little is you really then around question some what And space, Can there? more bit sales just traction.

you'll what's these guess, what's traction XXXX? get in terms the modifications from of in I expectation And the the then QX? So expectation for here

Charles Goodwin

Yes. Thanks, Matt.

my third mentioned, quarter listening not was I commercial team expectations. to got majority our execution sales had I team I've be great I because expectations. that our As overachieving meet the clear know and of this, did is our want to their a marketing that commercial we in And

from our obviously. impact And team marketing quarter, updated the this everybody the is that XX sales have QX. are they it to in into that contemplates obviously, implemented but make But sales we year, marketing, know and response and made the also knows team, fourth changes our the the improve so group from going to rest entire and productive long and change. we've of right the I sure expectations strategic want we this But guidance both reorganizations in that our of in run. that not more our to to believe, built in that be both -- But we're areas and in

Operator

of from with Hewitt come Craig-Hallum. questions the next Our line Matt

Matthew Hewitt

a education, first more the introducing approvals? of on saw we've there it's recent platform like your feel a international function kind there. will, now Maybe issue and and new past front, distributors? you customers kind the the rebound of of little if to Or safety the up, gotten like with regarding sounds Do still just working communication of you it you bit a is

Charles Goodwin

Yes. No, good it's question. very a

most I safety we the company. the to part, the it Google for going think still notice for part. up look comes the and people Obviously, are past are most if at

So now. we have for body obviously, the is we have contouring procedures. that, has have get answer, else kicker the safe how been obviously real huge the indications, that. specifically that it to year -- these always the have handle that these something on amount but a middle reps, indications saying FDA and then equipped of have because, that support and this this how helps distributors And our to final everybody those the is of clinical help now is And through technology effective and we'll tremendous talk is to And we then to that that that our to obviously just to data that.

we benefits moved So as Renuvion well for past to their we're up. get more But does we're customers to focused very that the how able make equipped get come see of the that and that most sure we've handle be if on to it patients. and we that, for part,

Matthew Hewitt

you your maybe the hearing separately, that initial quickly then practices you any quarter. handpieces that feedback the on And expect the something this it? this soft Micro ramp are using from launch? following to full What Is launch past are upon

Charles Goodwin

Yes.

and But are face, the where about handpiece. that obviously Micro of the talked also final Micro areas the are the now before. the for So stages in getting the has of Micro with specific great that's with the not surprise. it. success where X our areas. which the by right And the seeing We developing probably doctors that using we're good results protocols labia most some We're the very the handpiece reviews are been handpiece areas a they're also hands having specific

sometime And our Micro so material handpiece And that year. working like a clinical with expect contribution said, the would training. have work through next I would we to we're team through the

Operator

Stephens. the next come of Our from from Sellers questions line George

George Sellers

I'm the One placements market. of domestic still then where many also give the how some Apyx many you some curious or that were how placements of new in Apyx just legacy legacy One the with start U.S. customers you detail the split device your additional and device? using or -- legacy in between to to Apyx quarter sales in are out One device on the Maybe the could if the are rolling

Charles Goodwin

Yes.

don't generator new the have was But the from program sales sure Apyx numbers upgrade from our took else. okay? One. Apyx customers also of that break majority growth We we make did the customers, actual to we're and just down to of So U.S. the One who in to clear advantage everything the

so of from the sales but were of growth vast Apyx in vast that majority that -- XX% growth generators. One sold. that the of were And those came And the new happened majority U.S.

George Sellers

seen changes skin this That's are using in liposuction physicians helpful. Any sort breakout the on in underlying any or with changes And you market, how in versus device? growth of conjunction stand-alone then shifts have procedures stand-alone any or tightening? the in between

Charles Goodwin

they reasons And just patients that have of because having evidence good following it's lack of some and a very weight and Yes, question. Yes. of drugs on liposuction. them the is to success have as stand-alone GLP-X of a these the see modality one big that Renuvion for of are skin. started we then No, using instead lose

than to believe loose locks drugs a then that going address greatest the got they've to better benefit that skin, obviously, if so they're minimally going to the going be surgeons plastic is or see that And from they're because But there Renuvion. not over technology out to cosmetic or obviously, time. group invasively there's I GLP-X

provide to see for coming issue doctors And able a so are solution patients to starting being them. in that and with we

Operator

Our of with Turkaly questions the line from JMP Dave next come Securities.

David Turkaly

your volume? the aesthetic more on if what of research market of wondered sort broadly for you you affection you volumes? like just the life latest might expecting just share what And a how I sort specifically, procedure recession into and you're this I even are are for expecting? of of expecting What year not are year, next or procedures sort end guess,

Charles Goodwin

Yes.

as far data the -- just So doesn't the research reports we thing the quick change that go. so expect I as think first market as is

huge a some We beneficiaries surgeon. at have, volumes it be they CAGR going procedures a I -- in to cosmetic worldwide, going to And these the lose we in trying at mentioned or of plastic think because this. but weight. drugs when in keep for something And grew types would of and skin that go so see the to the be XXXX. have that many go but say, for that for growing, bigger to be body cosmetic in CAGR, a is over And probably would procedure is that going surgeons of to lack go do and years when of that think to years many, you create That marketplace previous years as been great to we now motivated and the see not to for are come. people many high the I skin come I and at for expect GLP-X going to kind years still are would a I liposuction lot contouring one, XX% are And laxity, single-digit all will do you to look need a expand lose plastic many, procedure saw to of weight rate. be something

Operator

Our of from next questions with line Hewitt come Matt the Craig-Hallum.

Matthew Hewitt

go think kind the energy advanced represented half remarks, in sales prepared your back of you I trailing your to said and million to you that, going I wanted sell to said obviously that to just in the continue it Charlie, be that really sales to your Is you're months. Follow-up the than generated the about now from expectation that will during that it's something now driving But revenues with over boxes. handpieces driver continue primary more that the handpiece to XX utilization here. going crossed median of that yes, $XX you've forward?

Charles Goodwin

a for based consumable and obviously math that the No, from the change just from the But what things Yes, amount that Matt, thanks, the things change is of Yes. of capital won't business our question. from and is of side quarter-to-quarter, look, perspective. vast we on thanks could driving sell amount utilization.

GPX as to in we adoption they're the because company passionate and and utilization That selling helping are incredible themselves and we achieve clinical of patients. with And have they team utilization. the capital always about very that about organization. certainly technology as an and keep to it ton more to because us patients, are want different and that for areas the it's users the treat are or is medicine office. tremendous a a of And results for time know, group passionate having and using a of we fortunate types whether their you've that on the you have different technology We been do instruments our areas is be going and able the amongst of of that spent for each they sit in of incredibly been how piece bringing to it that keep that and one focus allowing has and in LIFO our patients. to things for drive with evidence-based the talk of is driving story while, out a patients handpieces As an figure it doctor's not more them

For allowing give us, for provide patients practice technology utilization their this results. with these driving to and partnering focus the the great to and is them them that

will so driving has as high And focus, we as always that our can. and that we been number possibly keep

Operator

your showing for you for We does no are conference that, time. currently conclude With participation. at today. rewinning this that Thank questions our

disconnect. now may You

Apyx Medical (APYX) 9 Nov 232023 Q3 Earnings call transcript